CHICAGO, June 4, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced encouraging results from the Phase 1b portion of an ongoing Phase 1b/2 clinical trial of IPI-926 in combination with the chemotherapy gemcitabine (also known as Gemzar®) in patients with previously untreated, metastatic pancreatic cancer. The data, presented during a poster session at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), showed that IPI-926 in combination with gemcitabine was well-tolerated. In addition, partial responses were observed in five of 16, or 31 percent, of patients (Abstract #4114). The historic overall response rate to gemcitabine is less than 10 percent.i,ii
